CollPlant Biotechnologies Ltd. (CLGN)
| Market Cap | 94.35M |
| Revenue (ttm) | 6.02M |
| Net Income (ttm) | -7.26M |
| Shares Out | 6.96M |
| EPS (ttm) | -1.11 |
| PE Ratio | n/a |
| Forward PE | 96.15 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 22 |
| Last Price | $14.59 |
| Previous Close | $14.47 |
| Change ($) | 0.12 |
| Change (%) | 0.83% |
| Day's Open | 14.26 |
| Day's Range | 14.00 - 14.66 |
| Day's Volume | 8,761 |
| 52-Week Range | 6.24 - 15.76 |
REHOVOT, Israel, Nov. 10, 2020 /PRNewswire/ -- CollPlant (NASDAQ: CLGN) a regenerative medicine company, today announced its development program of an antiviral agent for potential treatment o...
REHOVOT, Israel, Sept. 16, 2020 /PRNewswire/ -- CollPlant (NASDAQ: CLGN) a regenerative and aesthetic medicine company, today announced that Dr.
REHOVOT, Israel, Aug. 31, 2020 /PRNewswire/ -- CollPlant (NASDAQ: CLGN) a regenerative and aesthetic medicine company, today announced that Dr.
REHOVOT, Israel, Aug. 28, 2020 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetics medicine company, today announced financial results for the second quarter ended June 30,...
Is (CLGN) Outperforming Other Medical Stocks This Year?
Is (CLGN) Outperforming Other Medical Stocks This Year?
CollPlant Holdings Ltd. Sponsored ADR (CLGN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects.
REHOVOT, Israel, May 27, 2020 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetics medicine company, today announced financial results for the first quarter ended March 31, ...
As of late, it has definitely been a great time to be an investor in CollPlant Biotechnologies.
These healthcare stocks have great financials now, and in the future. They all represent the future of medicine, and offer big growth.
CollPlant Holdings Ltd. Sponsored ADR (CLGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.
Top Ranked Momentum Stocks to Buy for October 11th
About CLGN
CollPlant Biotechnologies, a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bio-printing of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. The company's products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. Its products include BioInks for 3D printing of tissues and organs; dermal filler for treating wrinkles; 3D Bioprinted breast implants; VergenixSTR, a soft tissue repair matrix intended for... [Read more...]
| Industry Biotechnology | Founded 2004 |
| CEO Yehiel Tal | Employees 38 |
| Stock Exchange NASDAQ | Ticker Symbol CLGN |
Financial Performance
In 2019, CLGN's revenue was $2.32 million, a decrease of -53.77% compared to the previous year's $5.01 million. Losses were -$11.16 million, 78.7% more than in 2018.
Analyst Forecasts
According to one analyst, the rating for CLGN stock is "Buy" and the 12-month stock price forecast is 14.00.